Company Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.
The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Country | China |
| Founded | 2011 |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 138 |
| CEO | Peter P. Luo |
Contact Details
Address: Building C14, 4th Floor Suzhou, 215123 China | |
| Phone | 86 512 8777 3632 |
| Website | adagene.com |
Stock Details
| Ticker Symbol | ADAG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001818838 |
| CUSIP Number | 005329107 |
| ISIN Number | US0053291078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter P. Luo Ph.D. | Co- Founder, Chairman, Chief Executive Officer and President of Research & Development |
| Man Kin Tam M.B.A. | Chief Financial Officer and Director |
| Ling Zhou | Executive Director and Head of Human Resources |
| Dr. Qinghai Zhao Ph.D. | Chief Manufacturing Officer |
| Yan Li M.B.A. | Senior Vice President of Bioinformatics and Information Technology |
| Xiaohong She | Senior Vice President and Head of Clinical Operations |
| Dr. Guizhong Liu Ph.D. | Senior Vice President of Early Drug Discovery |
| Alexander Goergen | Vice President and Head of Business Development |
| Dr. Jiping Zha M.D., Ph.D. | Executive Vice President of Clinical Development |
| Dr. Songmao Zheng Ph.D. | Vice President and Head of Clinical and Quantitative Pharmacology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 24, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | SCHEDULE 13D/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | SCHEDULE 13G | Filing |
| Feb 3, 2025 | SCHEDULE 13G/A | Filing |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 6-K/A | Filing |